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Summary Backgrounct. In several studies, higher plasma levels of histidine-rich glycoprotein (HRG) have been
observed in patients with venous thrombosis than in healthy subjects. Apart from environmental factors, such äs the
use of oral contraceptives, the plasma HRG levels are mainly determined genetically. The most important genetic
determinant is P/S186 polymorphisms in exon 5 of the HRG gene which is associated with 40% higher HRG levels. In
this study we investigated the relationship between the HRG P/S 186 polymorphism and venous thrombosis.
Methods and Results: DNA was available from 466 patients and 471 controls of the Leiden Thrombophilia Study
(LETS), a population-based case-control study on venous thrombosis. Both in patients and controls, the genotype
distribution of the P/S186 polymorphism was not different from that predicted by the Hardy-Weinberg equilibrium. No
association between the genotypes of the P/S186 polymorphism and deep-vein thrombosis was found (PS 186
genotype: OR: 0.97 (01:0.24,1.70); SS 186 genotype: OR: 1.12 (01:0.21,2.04), PP 186 isthe reference category).
Conclusion: The results of this study suggest that the HRG P/S 186 polymorphism is not associated with first venous
thrombotic events.
INTRODUCTION
Histidine-rich glycoprotein (HRG) is a single-chain non-
enzymatic plasma glycoprotein that is synthesized by the
parenchymal cells of the liver.1·2 HRG may be active in
many physiological processes and it is considered to be
able to act äs a modulator of coagulation and fibrinolysis
through binding with heparin and plasrninogen
(reviewed in Koide).3 Whether HRG really contributes to
the in vivo fibrinolysis is still not clear,4·5 but in several
cross-sectional studies elevated plasma concentrations of
HRG were associated with venous thrombosis.15"10
fleceived: 9 September 1998
Accepfed after revision: 28 December 1998
Correspondence to: Dr M. P. M. de Maat, Gaubius Laboratory, TNO-PG, P.O.
Box 2215, 2301 CE Leiden, The Netherlands. Tel.: +31 71 5181502;
fax: +31 71 5181904;e-mail: M.deMaat@pg.tno.nl
HRG concentrations are influenced by genetic fac-
tors,1'·12 and by environmental factors such äs oestro-
gens,13·14 pregnancy15·"5 and age.7 Hennis et al.17 identified a
common molecular variant of HRG, which is caused by a
single base pair Substitution in exon 5 of the HRG gene,
resulting in a Substitution of proline 186 by serine.18 This
Substitution is associated with an increase in the mole-
cular weight, most likely by glycosylation of serine 186
(S 186) (unpublished results). The S186 allele was found to
be associated with ±40% higher levels of HRG in plasma
when measured with the irnmunodiffusion technique.19
Since the S/P 186 polymorphism accounts for 84% of
the total genetic influence of the HRG locus on the
plasma HRG level18 we postulated that the S/P 186 poly-
morphism may be used to evaluate the relationship
between plasma levels of HRG and thrombosis. In this
study we investigated the association between the S 186





Tlie Leiden Thrombophilia Study (LETS) is a population-
based case-control study on venous thrombosis. LETS
was set up with the aim of providing a direct comparison
between unselected patients with venous thrombosis and
an appropriate population-based venous-thrombosis-free
control group. The selection procedures for patients and
control subjects have previously been described in
detafl.20 Briefly, consecutive patients, less than 70 years,
who were referred for anticoagulant treatment after a
first, objectively confirmed, episode of deep-vein throm-
bosis occurring between January 1988 andJanuary 1993,
were selected from the files of the anticoagulation clinics
in Leiden, Amsterdam and Rotterdam. Each thrombosis
patient was asked to find their own healthy control sub-
ject according to the following criteria: same sex, about
the same age (plus/minus 5 years), no biological relative
and no history of venous thromboembolism, no use of
coumarins over the previous 3 months, not known to
have a malignant disorder and an inhabitant of the same
geographical area. Partners of patients were also invited
to serve äs control subjects for other patients who were
unable to find a control subject. For the present study
DNA was available from 466 patients and 471 controls.
ONA procedures
Enzymatic amplification of genomic DNA was performed
by polymerase chain reaction (PCR) in a final volume of
25 μΐ containing lOOng genomic DNA, 20mmol/l Tris-
HC1 pH 9.4, 50 mmol/1 KC1, 1.5 mmol/1 MgCl2, 50 μτηοΐ
dNTPs, 50 ng of each primer and 0. l unit Super Taq poly-
merase (HT Biotechnology Ltd., UK) according to the
manufacturer's instructions. The PCR reactions were per-
formed in a Hybaid Omnigene thermal cycler (Hybaid
Teddington, UK). The nucleotide sequences of the PCR
primers were 5'-CTGTTCITGAAACTATTTGATCC-3' and
5'-TGACTCTAGTCAACGATCAC-3' (Pharmacia Biotech,
the Netherlands) The PCR reaction started with 4 min at
95°C and proceeded for 30 cycles, each with a denatura-
tion step of l min at 95°C, anneabng for l min at 55°C
and extension for l min at 72°C. The PCR product was
digested overmght with l 2 units of BamI (New England
Biolabs, MA, USA) at 37°C. After digestion, the PCR prod-
uct was separated by electrophoresis using 4% agarose
gels in 0.5 x TBE buffer (0.045 mol/1 Tris, 0 044 mol/1
boric acid and l mmol/1 EDTA) containing ethidium bro-
mide, and visualized under uv light. Bantl digestion
yielded one band of 156 bp in the absence of the restnc-
tion site (common allele, P 186) and two bands of 84 bp
and 72 bp in the presence of the restnction site (rare
allele, S 186)
Statistical analysis
A χ2 test was used to compare the observed numbers oi
each genotype with those expected for a population m
Hardy-Weinberg equilibnum Logistic regression was
used to evaluate the nsk for venous thrombosis in those
carrying the S 186 allele
RESULTS
The general charactenstics of the total population and
separately for each genotype are shown in Table l There
was no difference in the frequency of the S 186-allele in
patients {0.34 (95% CI 031,037)} and in controls {035
(95% CI: 0.32,0 38)}, and also the genotype distnbution
was similar. The genotype distributions were m
Hardy-Weinberg equilibnum both for patients and con-
trols. In both the patients and the control group the
mean age and percentage of females was similar in each
genotype group.
No association between the P/S 186 polymorphism and
venous thrombosis was observed The odds ratios were
0.97 (95% CI: 024,1.70) for the PS Genotype and l 12
(95% CI: 0.21,2.04) for the SS genotype when the PP
genotype was taken äs a reference
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DISCUSSION
In the present study no association has been observed
between the HRG P/S 186 polymorphism and venous
thrombosis
The allele frequencies of the polymorphism in the con-
trols were similar to those in healthy volunteers reported
in a previous study '7 The genotype distnbution for
patients and controls was similar which suggests that
patients and controls ongmated from the same source
population This supports our fmdmg of no mcreased nsk
of venous thrombosis m those carrymg the S allele
Twm studies have shown that 70% of the vanance in
plasma HRG levels, äs measured by radial immunodiffu-
sion, can be explamed by genetic factors, mainly (84%)
by the P/S 186 polymorphism The rest is explamed by
other, äs yet unknown, genetic factors 1Ä Recently, it was
leported that the radial immunodiffusion assay for
plasma HRG, which is based on a polyclonal anübody
agamst HRG, shows a different specificity towards the
two vanants of the P/S 186 polymorphism It has been
found that higher HRG levels were recorded for the mol-
ecular form contaimng the glycosylated S 186 than that
tontainmg the non-glycosylated P186 ]9 In subjects with
the SS 186 genotype the HRG levels, äs measured using
immunodiffusion, appear to be 40% higher than the lev-
els m subjects with the PP 186 genotype, while heterozy-
gotes have levels that are mtermediate
This high contnbution of the P/S 186 polymorphism to
plasma HRG levels, äs measured with immunodiffusion,
tombmed with our observation that there is no relation-
ship between the S 186 allele and the incidence of
venous thrombosis, may suggest that there is also no
association between plasma concentrations of HRG and
venous thrombosis This conclusion would be in line
with results from some previous studies,"1 however, in
other studies a positive relationship between HRG levels
and thrombosis was reported 6~'° This suggests that other
factors which influence plasma HRG levels may play a
role in the association of HRG and thrombosis äs
observed in previous studies °"10 In conclusion, the
results presented here indicate that the HRG P/S 186
polymorphism is not related to venous thrombosis
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